A phase 2, randomized, double-blind, placebo-controlled trial conducted by Maher et al. in 2021 has recruited about 500 patients with IPF to evaluate the efficacy and safety of lebrikizumab (IL-13 monoclonal antibody), alone or with background pirfenidone therapy [34]. Here, IL13 is linked to idiopathic pulmonary fibrosis.